Herantis Pharma publishes newsletter for July-August

We were honored to participate in the Neurotrophic factors and Parkinson’s meeting. Dr. Hartiala was awarded EURAP's best presentation when presenting our Lymfactin® clinical study in April. Herantis' team grew with two new colleagues.

Herantis Pharma Plc
Company release 02 Sep 2019 at 7:00 am

Herantis Pharma publishes newsletter for July-August

Herantis Pharma Plc
Press release 2 September 2019 at 9:00 am

Herantis Pharma plc (“Herantis”) has published its newsletter for July-August 2019. The newsletter is also attached to this press release.

Herantis’ newsletter is published every other month on the company’s web site. It is also available by email subscription.

Further information:

Herantis Pharma plc, Pekka Simula, CEO, telephone: +358 40 7300 445
Company web site: www.herantis.com

About Herantis Pharma Plc

Herantis Pharma Plc is an innovative drug development company focused on regenerative medicine and unmet clinical needs. Our clinical stage assets CDNF and Lymfactin® are based on globally leading scientific research in their fields. They both aim at breakthrough in the treatment of severe diseases: CDNF in neurodegenerative diseases such as Parkinson’s disease; and Lymfactin® in breast cancer associated lymphedema with potential also in other lymphedemas. The shares of Herantis are listed on the First North Finland marketplace run by Nasdaq Helsinki stock exchange.

Distribution:

Main media
www.herantis.com

Attachment